In the UK, memory loss is considered one of the most common health fears, especially as we get older.

In a study conducted by Alzheimer’s Society, 57% of participants revealed that they would wait to speak to a doctor about new memory loss symptoms out of fear. However, an early Alzheimer’s diagnosis is the easiest way to access new treatments, which can then help slow cognitive decline.

One of the easiest ways to test for Alzheimer’s is through a new quick and simple blood test. Read on to learn more about how the new LucentAD® pTau217 Alzheimer’s blood test can support earlier identification of potential risk.

The first of its kind: The LucentAD® pTau217 Alzheimer’s blood test

Launched in the UK in November 2024, the LucentAD® pTau217 Alzheimer’s blood test is transforming how we detect and understand Alzheimer’s disease, especially in its earliest and most subtle stages.

Supported by both Alzheimer’s Society and Alzheimer’s Research UK, biomarker tests, such as the LucentAD® pTau217 test, measure key factors directly linked to the build-up of amyloid and tau proteins within the brain. Both of which are two key hallmarks of Alzheimer’s.

Why consider the LucentAD® pTau217 Alzheimer’s blood test over a traditional brain imaging scan??

In the past, an Alzheimer’s diagnosis typically relied on the NHS pathway, which can be both time-consuming and invasive. This diagnostic route typically involves multiple medical history discussions with a GP, cognitive assessments, brain imaging, and sometimes the use of a lumbar puncture procedure to analyse spinal fluid. 

The most effective brain imaging test used in Alzheimer’s diagnosis is a PET scan, used to detect amyloid plaques. These are abnormal protein clusters within the brain, widely recognised as a key marker of Alzheimer’s. However, these scans often require referral to a specialist centre with lengthy waiting times. 

In comparison, Alzheimer’s blood tests require a simple blood sample to detect abnormal levels of the pTau217 biomarker. While these diagnostic tools may still be used to confirm a dementia diagnosis, the revolutionary LucentAD® pTau217 Alzheimer’s blood test offers a simpler, less invasive, and more cost-effective way to gain early insight into memory loss symptoms.

How does the pTau217 Alzheimer’s test work?

Phosphorylated tau 217 (pTau217) is one of the most widely studied biomarkers linked to Alzheimer’s disease, cognitive decline, and memory loss symptoms. Tau is a naturally occurring protein within the brain which helps stabilise nerve cells and supports normal brain function. 

In individuals with Alzheimer’s disease, these tau proteins can experience abnormal chemical changes. These changes can then cause the proteins to form “tangles” within the brain cells, further disrupting communication between neurons and contributing to further cell damage over time. 

Once the blood sample is taken, the LucentAD® pTau217 blood test is sent to our testing lab, Advance Tests, where specialist technicians will measure the level of modified tau proteins within the bloodstream. An elevated level of modified tau proteins may indicate biological changes linked to Alzheimer’s disease.

These tests are a popular choice for those with memory loss symptoms or a family history of Alzheimer’s because these cell adaptations can appear on the test years before cognitive symptoms become noticeable.

Please note: Results should always be interpreted in discussion with a qualified healthcare professional. Biomarker levels alone cannot confirm an Alzheimer’s diagnosis.

How accurate is the pTau217 test?

The acute pTau217 blood test is considered to be one of the most promising and accurate developments in modern Alzheimer’s diagnostics. 

Studies have shown that the LucentAD® pTau217 blood test for Alzheimer’s can achieve accuracy levels of approximately 80% to 90%, particularly when identifying the presence of Alzheimer’s related biological changes. 

These accuracy ratings have also been reinforced by strong correlations between pTau217 blood tests and results from established diagnostic tools such as PET brain scans, which are traditionally used to diagnose Alzheimer’s. 

However, it is important to note that this type of blood test is still developing. An Alzheimer’s blood test should be used to identify biomarkers associated with risk rather than for providing a definitive diagnosis. 

Who should get tested for Alzheimer’s?

Private Alzheimer’s blood testing is becoming increasingly common in the UK thanks to the accessibility, speed, and reliability of the tests. 

The most common high-risk groups exploring the option of Alzheimer’s blood testing include:

• Adults aged 50-70 concerned about their cognitive health
  

• Individuals experiencing early signs of memory loss (examples include forgetting recent events, repeating questions, misplacing items, experiencing confusion with time and places, etc.)
  

• People with a family history of Alzheimer’s disease or dementia
  

While occasional memory lapses are common and often unrelated to dementia, individuals experiencing ongoing concerns should always discuss their symptoms or blood test results with their GP or a trusted healthcare professional.

What do my Alzheimer’s blood test results mean?

If you take an Alzheimer’s biomarker blood test, your results will show whether pTau217 proteins are within a normal range or considered elevated.

A result revealing elevated pTau217 biomarkers does not necessarily mean you will develop Alzheimer’s disease, but it may warrant a further discussion with a healthcare professional. Similarly, results showing lower biomarker levels do not guarantee that Alzheimer’s will never develop.

Healthcare providers should use your biomarker results as well as the following information, in conjunction with further assessments if necessary, for an accurate diagnosis:

• Your medical history
  

• Your cognitive symptoms
  

• Your lifestyle factors
  

• Your family history

Book a private Alzheimer’s blood test with Goodbody Clinic

If you’d like to better understand your cognitive health markers and gain early insight into your Alzheimer’s risk in more detail, private Alzheimer’s blood testing in the UK is becoming an increasingly accessible option thanks to the rollout of the new Alzheimer’s blood test.

At Goodbody Clinic, we offer the LucentAD® pTau217 blood test as a simple in-clinic or at-home test option to suit your needs. 

With hundreds of Goodbody Clinic locations across the UK, from Aberdeen to Guernsey, reliable preventative health screening is never too far away. Whether you’re experiencing memory loss symptoms or are simply seeking peace of mind, taking a proactive approach to your cognitive health could make all the difference.